{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:25:21Z","timestamp":1777890321542,"version":"3.51.4"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Current genetic risk stratification systems for acute myeloid leukemia (AML), including the 2017 European Leukemia Network (ELN), 2022 ELN, and 2023 China (CN) stratifications, inconsistently categorize key genetic variants such as\n                      <jats:italic>CEBPA<\/jats:italic>\n                      and\n                      <jats:italic>FLT3-ITD<\/jats:italic>\n                      . These systems also demonstrate limited applicability to Chinese patients, complicating clinical decision-making. This study optimized genetic stratification for Chinese AML patients and developed a multi-omics prognostic model by integrating immunophenotypic and clinical characteristics to enhance outcome prediction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled 378 Chinese AML patients (298 for training, 80 for external validation) and compared the prognostic performance of the 2017\/2022 ELN and 2023 CN systems (both integrating molecular genomic and cytogenetic data). Controversial genetic variants were re-evaluated to establish a novel 2023 CN (n-2023 CN) classification. A multi-omics model was constructed by combining n-2023 CN classification with CD15 positivity (leukemic immunophenotype), del(7q) (cytogenetic abnormality), and age \u2265 60 years (clinical factor). The model underwent external validation, was assessed for use in guiding hematopoietic stem cell transplantation (HSCT), and was compared with a published model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 2023 CN demonstrated superior efficacy in predicting AML relapse and 3-year relapse-free survival compared to 2017\/2022 ELN systems. The n-2023 CN reclassified\n                      <jats:italic>CEBPA<\/jats:italic>\n                      <jats:sup>bZIP<\/jats:sup>\n                      as favorable-risk, t(8;21)\/inv(16) with\n                      <jats:italic>KIT<\/jats:italic>\n                      <jats:sup>D816<\/jats:sup>\n                      \/\n                      <jats:italic>FLT3-ITD<\/jats:italic>\n                      <jats:sup>low<\/jats:sup>\n                      as intermediate-risk, and\n                      <jats:italic>FLT3-ITD<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      as adverse-risk among patients not receiving\n                      <jats:italic>FLT3<\/jats:italic>\n                      inhibitors (regardless of\n                      <jats:italic>NPM1<\/jats:italic>\n                      co-mutation). CD15 positivity, del(7q), and age \u2265 60 years were independent adverse prognostic factors for overall survival (OS). The model stratified patients into three risk groups with significantly distinct complete remission (CR) rates (93.2%, 71.2%, 35.7%) and OS (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;\u00a00.001), with a concordance index of 0.729 (internal) and 3-year OS AUC of 0.752 (external). High-risk patients receiving HSCT exhibited longer OS. The model outperformed a published comparator in predicting CR and 1- and 3-year OS (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2264 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The n-2023 CN resolves uncertainty in genetic risk stratification for Chinese AML patients. The novel multi-omics model incorporates immunophenomics and clinical and cytogenetic factors, captures comprehensive AML characteristics, enhances prognostic precision, and provides reliable guidance for personalized treatment, including HSCT selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1812970","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:26Z","timestamp":1777613726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics integration of molecular genetics, cytogenetics and immunophenotyping: a novel prognostic model for immune landscape characterization and outcome prediction in Chinese patients with acute myeloid leukemia"],"prefix":"10.3389","volume":"17","author":[{"given":"Fengli","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Jiangnan University","place":["Wuxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanglong","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzhao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunyi","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinli","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanqiu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianshan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Hematological Lab, The Second Hospital of Anhui Medical University","place":["Hefei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.09.001","article-title":"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)","volume":"44","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2022","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-023-00835-5","article-title":"Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group","volume":"13","author":"Sargas","year":"2023","journal-title":"Blood Cancer J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1165445","article-title":"The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients","volume":"10","author":"Wang","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26892","article-title":"Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia","volume":"98","author":"Lo","year":"2023","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3324\/haematol.2023.283606","article-title":"Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia","volume":"109","author":"Park","year":"2023","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7891","article-title":"Association between increased mutation rates in DNMT3\u03b1 and FLT3-ITD and poor prognosis of patients with acute myeloid leukemia","volume":"18","author":"Zhang","year":"2019","journal-title":"Exp Ther Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20186327","article-title":"Clinical and pathological features of myeloid leukemia cutis","volume":"93","author":"Li","year":"2018","journal-title":"Bras Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223013","article-title":"Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy","volume":"14","author":"Ballo","year":"2019","journal-title":"PloS One"},{"key":"B15","article-title":"Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients","volume":"52","author":"Daneshbod","year":"2005","journal-title":"Neoplasma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-024-2711-y","article-title":"Not just a combination: a fully-integrated strategy of cellular therapy for acute myeloid leukemia expressing CD7, a heretofore elusive target","volume":"68","author":"Gorin","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/proteomes13010011","article-title":"Proteomic comparison of acute myeloid leukemia cells and normal CD34+ bone marrow cells: studies of leukemia cell differentiation and regulation of iron metabolism\/ferroptosis","volume":"13","author":"Selheim","year":"2025","journal-title":"Proteomes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3401","article-title":"A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia","volume":"91","author":"Legras","year":"1998","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1186\/s12885-022-10460-3","article-title":"Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia","volume":"22","author":"Liang","year":"2022","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/10428199909083383","article-title":"Expression of the C-Kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance","volume":"34","author":"Schwartz","year":"1999","journal-title":"Leukemia Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20526","article-title":"Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis","volume":"81","author":"Graf","year":"2006","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.15419\/bmrat.v10i8.822","article-title":"Acute myeloid leukemia with 8:21 translocation and aberrant B-marker expression","volume":"10","author":"Saidin","year":"2023","journal-title":"Biomed Res Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2450\/BloodTransfus.786","article-title":"The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia: the tandem CLL1\/CD33 CAR-T to treat AML","volume":"23","author":"Wang","year":"2025","journal-title":"Blood Transfusion"},{"key":"B24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1186\/s12967-025-06827-2","article-title":"Novel loop structure of human IgG1 Fc fused CD38 targeted bispecific antibodies and their anti-tumor effect in acute myeloid leukemia","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02644-0","article-title":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)","volume":"39","author":"Cusan","year":"2025","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02631","article-title":"Risk stratification in older intensively treated patients with AML","volume":"42","author":"Versluis","year":"2024","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-022-00700-x","article-title":"A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries","volume":"12","author":"B\u00e9rard","year":"2022","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.023","article-title":"Age and modified European LeukemiaNet classification to predict transplant outcomes: an integrated approach for acute myelogenous leukemia patients undergoing allogeneic stem cell transplantation","volume":"21","author":"Oran","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015797","article-title":"A revised prognostic model for patients with acute myeloid leukemia and first relapse","author":"Van Der Maas","year":"2025","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/genes12081144","article-title":"The genetics of myelodysplastic syndromes: clinical relevance","volume":"12","author":"Chiereghin","year":"2021","journal-title":"Genes"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41467-023-36193-w","article-title":"Myelodysplastic syndrome associated TET2 mutations affect NK cell function and genome methylation","volume":"14","author":"Boy","year":"2023","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8196","article-title":"Genomic landscape of DNA repair genes in cancer","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2019.100187","article-title":"Mutations of FLT3 receptor affect its surface glycosylation, intracellular localization, and downstream signaling","volume":"13","author":"Takahashi","year":"2020","journal-title":"Leukemia Res Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.13772","article-title":"Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after cord blood transplantation","volume":"19","author":"Akahane","year":"2019","journal-title":"Geriatrics Gerontology Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071737","article-title":"CXCR4 inhibition enhances efficacy of FLT3 inhibitors in FLT3-mutated AML augmented by suppressed TGF-\u03b2 signaling","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/TCRM.S434556","article-title":"Treatment patterns and FLT3 mutation testing among patients with acute myeloid leukemia in China: a retrospective observational study","volume":"20","author":"Gong","year":"2024","journal-title":"Ther Clin Risk Manag"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00277-026-06762-2","article-title":"Long-term follow-up of predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial","volume":"105","author":"Jiang","year":"2026","journal-title":"Ann Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02382-9","article-title":"Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia","volume":"38","author":"Wang","year":"2024","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6696","article-title":"Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2026.2620366","article-title":"Recent developments in overcoming FLT3 inhibitor resistance","volume":"18","author":"Kang","year":"2026","journal-title":"Future Med Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01144-1","article-title":"Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia","volume":"14","author":"Liu","year":"2024","journal-title":"Blood Cancer J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1182\/blood.V128.22.2785.2785","article-title":"The prognostic impact of KIT D816 mutations in core binding factor acute myeloid leukemia","volume":"128","author":"Yui","year":"2016","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1919660","article-title":"Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia","volume":"62","author":"Jin","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01384-w","article-title":"Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11","volume":"56","author":"Cho","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361025","article-title":"KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia","volume":"59","author":"Chen","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.51","article-title":"Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome","volume":"6","author":"Cher","year":"2016","journal-title":"Blood Cancer J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","article-title":"Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11","volume":"4","author":"Ishikawa","year":"2020","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061552","article-title":"Novel histopathological biomarkers in prostate cancer: Implications and perspectives","volume":"11","author":"Kie\u0142b","year":"2023","journal-title":"Biomedicines"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092203","article-title":"Prognostic and therapeutic role of CD15 and CD15s in cancer","volume":"14","author":"Szlasa","year":"2022","journal-title":"Cancers"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30440","article-title":"Toward \u03b1-1,3\/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6","volume":"124","author":"Magdaleno","year":"2023","journal-title":"J Cell Biochem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2021.2016800","article-title":"An introduction to the relationship between Lewis x and Malignancy mainly related to breast cancer and head neck squamous cell carcinoma (HNSCC)","volume":"40","author":"Croce","year":"2022","journal-title":"Cancer Invest"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwab083","article-title":"Major differences in glycosylation and fucosyltransferase expression in low-grade versus high-grade bladder cancer cell lines","volume":"31","author":"Ezeabikwa","year":"2021","journal-title":"Glycobiology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00345-018-2503-4","article-title":"Molecular markers in bladder cancer","volume":"37","author":"Soria","year":"2019","journal-title":"World J Urol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7150\/thno.33858","article-title":"Carcinoembryonic antigen carrying SLeX as a new biomarker of more aggressive gastric carcinomas","volume":"9","author":"Gomes","year":"2019","journal-title":"Theranostics"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0569","article-title":"Glycosylation is a global target for androgen control in prostate cancer cells","volume":"24","author":"Munkley","year":"2017","journal-title":"Endocrine-Related Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00523","article-title":"Immunohistochemical analysis of cancer stem cell marker expression in papillary thyroid cancer","volume":"10","author":"Kim","year":"2019","journal-title":"Front Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov248","article-title":"TNF-\u03b1 enhancement of CD62E mediates adhesion of non\u2013small cell lung cancer cells to brain endothelium via CD15 in lung-brain metastasis","volume":"18","author":"Jassam","year":"2016","journal-title":"Neuro Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2331","article-title":"Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia","volume":"35","author":"Chisini","year":"2017","journal-title":"Hematological Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5288","article-title":"CD15 expression on leukemic cells associates with extramedullary infiltration and adverse outcomes in acute myeloid leukemia","volume":"146","author":"Li","year":"2025","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13046-019-1179-y","article-title":"MiR-29b\/Sp1\/FUT4 axis modulates the Malignancy of leukemia stem cells by regulating fucosylation via Wnt\/\u03b2-catenin pathway in acute myeloid leukemia","volume":"38","author":"Liu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1059978","article-title":"Establishment of a risk model\u00a0correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia","volume":"12","author":"Bin","year":"2022","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1812970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:29Z","timestamp":1777613729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1812970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2026.1812970"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1812970","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1812970"}}